Background: Calcific aortic valve disease (CAVD) is a multifactorial condition characterized by progressive leaflet calcification with a potential role for bacterial colonization in its pathogenesis. This study investigates clinical, microbiological and molecular features of calcified versus non-calcified aortic regurgitation (AR) valves.
Methods: This is a prospective, observational study, whose primary objective was to compare the occurrence of bacterial detection between CAVD and AR. The secondary objectives included the evaluation of bone-related calcification markers in valves from CAVD and AR patients.
Results: We analysed 31 CAVD and 8 AR valves, yielding 111 leaflets (84 calcified, 27 non-calcified). Light microscopy of CAVD leaflets revealed near-complete disruption of the three-layered valve architecture, with calcified masses extending through the leaflets, sparse cellularity and focal micro-angiogenesis; no bacteria were detected by GRAM, PAS or TEM. Enrichment culture detected low-virulence bacteria in 5.95% of CAVD and 4.16% of AR leaflets; 16S rRNA PCR was positive in 22.5% of CAVD and 12.5% of AR cases, with Staphylococcus and Streptococcus spp. predominating. Calcium content was significantly higher in CAVD leaflets (p = .001) and correlated with dyslipidemia (p = .02). Osterix expression was higher in valves with positive microbiological findings (p < .0001), while ALP was increased in CAVD and bicuspid valves regardless of microbial status. Valve interstitial cells from CAVD exhibited spontaneous in vitro calcification, unlike controls.
Conclusion: The early osteogenic marker osterix was found to be upregulated in patients whose valves tested positive for microbial DNA, suggesting a potential role for bacteria in driving cellular differentiation towards an osteoblastic phenotype in CAVD.
Keywords: VIC; calcific aortic valve disease; osteoblast; osterix; staphylococcus spp.; streptococcus spp..
© 2026 The Author(s). European Journal of Clinical Investigation published by John Wiley & Sons Ltd on behalf of Stichting European Society for Clinical Investigation Journal Foundation.